COPD

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

The Q1 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

March 2026 saw new data from pivotal clinical trials and new expert conversations on HCPLive.

AstraZeneca's investigational IL-33–targeting antibody tozorakimab met its primary endpoint in both the phase III OBERON and TITANIA trials.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

At AAAAI 2026, Ramsey discussed the shift toward race-neutral spirometry equations, their clinical implications, and barriers to widespread adoption.

New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.

Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.

February 2026 saw new data and expert interviews from AAAAI 2026.

Using race-neutral spirometry equations such as GLI 2012 and GLI 2022 may improve diagnostic accuracy and reduce disparities in lung disease assessment.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

A clinical forum focuses on how advanced practice providers (APP) and clinicians are now navigating how to translate emerging data into real-world practice.

These retrospective cohort studies also showed the vaccine’s reduction of heart attack, stroke, and asthma/COPD flare-ups in patients with RSV.

A clinical forum brought together pulmonologists and advanced practice providers to share their experiences navigating the changing COPD and asthma landscape.

January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.

In this Q&A, Mathioudaki discusses the post-hoc FLAME trial, which links ICS and LAMA discontinuation to transient exacerbation risk in COPD.

Fortis discusses new data that challenge the use of bronchodilator response as a tool for distinguishing asthma from COPD.

COPDGene data show bronchodilator response more accurately predicts FEV₁ decline and disease progression than polygenic risk scores, including among smokers with preserved spirometry.

Post-hoc analysis of the FLAME trial shows treatment discontinuation in COPD is associated with transient withdrawal effects and increased exacerbation risk.

Experts discussed how biologics revolutionize asthma and COPD management, emphasizing personalized treatment strategies and proactive care.

A study found that bronchodilator responsiveness more accurately forecasts FEV₁ decline and COPD development than polygenic risk scores.